Articles related to GYNECOLOGICAL CANCERS

Experts discussing rising breast cancer diagnoses cite both incidence increases and improved detection, alongside persistent concerns about diagnostic delays. The commentary does not establish that more patient-centered care explains the increase.

A Georgia woman alleges that a pathology specimen mix-up led to an erroneous cancer diagnosis and an unnecessary hysterectomy. The lawsuit highlights the potential consequences of laboratory identification failures and diagnostic verification breakdowns.

PCOS was associated with significantly elevated risk for breast, uterine, ovarian/fallopian tube, and cervical cancers in a matched cohort of more than 2.5 million women.

Long-term follow-up from the phase 3 NRG-GY018 trial showed sustained overall survival benefit for pembrolizumab plus carboplatin-paclitaxel in dMMR endometrial cancer at 48 months, while the pMMR OS advantage did not reach statistical significance despite a 9-month median improvement.

An ESMO express update to epithelial ovarian cancer guidelines added rucaparib and mirvetuximab soravtansine as treatment options, but expert commentary and two subsequent FDA approvals have raised questions about the update’s current clinical applicability.

Treatment options for platinum‑resistant ovarian cancer remain limited. New phase 3 survival data suggest that adding a novel agent to standard chemotherapy may meaningfully extend survival for this hard‑to‑treat population.